TrialJournal for immunotherapy of cancer2024

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.

Caicun Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.